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ADHD is the most commonly diagnosed Axis I mental health disorder in children with 
prevalence estimates of 3% to 5% of US children.  The preponderance of ADHD research has 
focused on behavioral problems, while a much smaller proportion of research has focused on 
cognitive aspects.  The purpose of this study was to examine stimulant medication effects on 
memory in children with ADHD.  METHOD: Thirty-five children (26 males and 9 females) with 
the diagnosis of ADHD (subtypes included predominately inattentive, predominately 
hyperactive, and combined) were mostly obtained from local pediatric clinics.  The Wide Range 
Assessment of Memory and Learning, 2nd Edition (WRAML2) was administered along with the 
Wechsler Abbreviated Scale of Intelligence (WASI) over 2 sessions, 1 of which the participants 
were on their prescribed medication, and 1 of which was a placebo condition.  Participants and 
Examiner were blind to condition.  CONCLUSION: Contrary to expectation, there was no 
difference between participant performance when on medication vs. placebo for the WRAML2 
subtests (Wilks λ = .66, F(15, 19) = .65, p > .05) or WASI subtests (Wilks λ = .81, F(4, 30) = 
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1.71, p > .05).  Therefore, stimulant medication had no demonstrable effect on memory 
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“For over 20 years, Attention Deficit Hyperactivity Disorder (ADHD) has been viewed 
as comprising three primary symptoms, these being poor sustained attention, impulsiveness, and 
hyperactivity” (Barkley, 1997a, p. 65).  Difficulties in these three areas are often broadly 
classified as difficulties with executive functioning.  Executive functioning has been defined as 
the capacities to engage in independent, purposive, and goal-directed behavior (Busch et al., 
2005).  These higher-order processes enable us to incorporate feedback and make behavioral 
adjustments in accordance with environmental demands.  Other abilities subsumed under the 
broad category of executive functioning include attention, planning, organization, initiation, self-
monitoring, response inhibition, and generative behavior (Busch et al., 2005).  Executive 
functioning abilities are considered to be critically important for complex human behavior, and 
their breakdown is thought to commonly result in behavioral or psychiatric impairment (Fisher, 
Barkley, Smallish, & Fletcher, 2005).  
The topic of Attention Deficit Hyperactivity Disorder (ADHD) has been significantly 
researched.  In a simple search of PsychINFO for the terms ADHD from 1998 to the present, 
there were over 6,000 articles that were found.  With the abundance of information concerning 
ADHD it is difficult to cover all of the research that has been generated, however the most 
salient research is summarized throughout this chapter.   
Effects of Medication on Memory     2 
 
 
 ADHD is generally considered a lifelong disorder that is not solely a function of a single 
environmental stressor.  As a result, the Diagnostic and Statistical Manual of Mental Disorders – 
IV (DSM-IV; American Psychiatric Association, 2000) specifies that ADHD symptoms must be 
present early in childhood, must continue for an extensive period of time, and must be displayed 
in more than one setting.  There is currently no compelling evidence that ADHD in adolescents 
is qualitatively different from the disorder in children, or adults for that matter (Barkley, 2004).  
Critical in the classification of ADHD is the presence of several subtypes.  Based on the two core 
symptom clusters, the DSM-IV defines three subtypes of ADHD: a primarily hyperactive-
impulsive type, a primarily inattentive type, and a combined type (Lahey, et al., 1994).  
Specifically, those children with the problems of inattention without high rates of impulsivity 
and hyperactivity tend to show fewer conduct problems and less peer rejection, and are more 
anxious and shy than those children who are also impulsive and hyperactive.  The inattentive 
subtype also “mainly involve students with academic impairment” (McCormick, 2003, p. 621).  
The hyperactive and inattentive subtypes may also show differences in the types of attentional 
processes that are deficient, and the inattentive type shows a different response curve to 
stimulant medication (Barkley, DuPaul, & McMurray, 1991).  The inattentive and distractible 
behavior distinguishes ADHD from learning disabilities or other psychiatric disorders and does 
not appear to be a function of the other disorders often comorbid with ADHD (anxiety, 
depression, or oppositional and conduct problems; Barkley, Edwards, Laneri, Fletcher, & 
Metevia, 2001a).  A study by O’Driscoll et al. (2005) found that children with ADHD combined 
subtype displayed more difficulties on tasks of executive functioning than children with ADHD 
inattentive subtype.        
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ADHD is the most commonly diagnosed Axis I mental disorder in children (Barkley, 
1997b).  Prevalence estimates vary widely as a function of diagnostic criteria used, but 
reasonable estimates suggest that 3% to 5% of children nationwide are affected (Barkley, 
1997b).  Because ADHD accounts for a large proportion of all referrals for pediatric mental 
health services, at great economic and emotional expense, the development of effective 
treatments cross the childhood and adolescent years is essential (Hibbs & Jensen, 2005) 
Although deficits in attentional abilities and other areas of cognitive functioning are 
extremely problematic for children with ADHD, much of the research on the disorder has 
focused on the behavioral problems and the perceived accompanying social disruptions 
associated with it (DeShazo, Klinger, Lyman, Bush, & Hawkins, 2000).  This leaves minimal 
research regarding the core cognitive and memory impairments associated with the disorder.  
“Cognitive domains such as verbal working memory, internalized speech, emotional self-control, 
and cross temporal organization of behavior become progressively more elaborate in adolescents 
and consequently may be more affected by the disorder than they were in childhood” (Barkley, 
2004, p. 40).  Many studies that have investigated the cognitive abilities of children with ADHD 
have promoted the theory that the disorder involves frontal lobe dysfunction (Barkley, 1997b).     
Neuropsychological research has suggested that certain regions of the brain may be 
implicated in the disorder.  Deshazo, Klinger, Lyman, Bush, and Hawkins (2000) found that the 
performance of boys with ADHD on visual cueing tasks was not impaired relative to controls, 
whereas the performance of the same boys with ADHD on a continuous performance test was 
significantly impaired.  The results suggest dissociation between selective and sustained attention 
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abilities in children with ADHD and implicate the frontal lobe region as a specific area 
associated with the impairment.   
Impulsivity and inattention are the most reported symptoms of ADHD, however the poor 
performance of children with ADHD on cognitive tasks cannot be explained exclusively by 
inhibitory or attention control deficits (Shue & Douglas, 1992), suggesting that this impaired 
performance may be representative of a higher order cognitive deficit.  Research by Pennington 
and Ozonoff (1996) suggested that children with ADHD may demonstrate difficulties in higher 
order executive functioning processes such as planning, organization, and problem-solving 
ability, while inattention and impulsivity may be secondary to these more global deficits.  Since 
ADHD involves deficits in global functions, then impairments in attentional processes and 
impulse control would also be expected.   
ADHD and Academic Performance 
Children with ADHD are traditionally academic underachievers, a problem that appears 
to be distinct to ADHD when compared to other disruptive behavior disorders, such as conduct 
disorder (Frick et al., 1991).  Frick and Lahey (1991) found that as many as 30% of children with 
ADHD do not achieve academically at the level predicted by their age or IQ.  Although this 
finding may be interpreted as a problematic behavior which then interferes with academic 
achievement, it may also be that children with ADHD have specific cognitive impairments that 
hinder learning (Deshazo, 2001).   
      Children whose, “primary difficulties are with inattention more closely resemble children 
with learning disabilities in their academic difficulties and associated behavioral difficulties” 
(Shelton & Barkley, 1994, p. 31).  The percentage of children experiencing some delay in the 
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onset of talking may be somewhat higher for children with ADHD (6% - 35%) than for those 
without ADHD (2% - 5. 5%; Shelton & Barkley, 1994).  While not all children may have deficits 
in language functioning, the language difficulties that some children with ADHD encounter may 
be due to their difficulties with higher order cognitive processes.  Depending on the definition, 
approximately 25% to 50% of the children with ADHD will have at least one type of learning 
disability, either in math, reading, or spelling (Shelton & Barkley, 1994).   
Research has suggested that deficits in problem-solving and other cognitive processes are 
likely linked with the poor academic performance associated with ADHD (McCormick, 2003).  
For example, in addition to slower computational performance in mathematics, which may be 
behavioral, children with ADHD also have been shown to score lower on measures of their 
problem-solving ability in conceptual math (Zentall, Smith, Lee, & Wieczorek, 1994).  
Specifying these cognitive impairments and their relation to academic achievement is still 
unknown, however important to begin the subsequent process of identifying the possible causes 
of underachievement in children with ADHD.   
Attention and Inhibition 
      Attention represents a multidimensional construct.  The dimensions impaired in ADHD 
reflect an inability to sustain attention or persist at tasks, remember and follow through on rules 
and instructions, and resist distractions while doing so (Bates, Mathias, & Crawford, 2001).  By 
adolescence, this dimension more likely reflects problems with working memory than poor 
attention (Seguin, Boulerice, Harden, Tremblay, & Pihl, 1999).  These difficulties can be more 
broadly explained by four executive functions: operation of working memory; internalization of 
self-directed speech; controlling mood, motivation and arousal; and reconstitution (the ability to 
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break down and recombine behaviors; Bates, Mathias, & Crawford, 2001).  These actions are all 
important because they permit self-regulation in an individual.  The attention and regulation 
given to these concepts is often minimal in children and adolescents with ADHD.  
  As with attention, inhibition is a multidimensional construct.  The problems with 
inhibition seen in ADHD seem to involve voluntary or executive inhibition of proponent 
responses.  More specifically, teens with ADHD manifest difficulties with restlessness, less 
ability to stay seated when required, talking excessively, acting impulsively, and interrupting 
others’ activities (Nigg, 2001).  In particular, delaying gratification and valuing future over 
immediate rewards is difficult for the adolescent with ADHD.  These inhibitory deficits extend 
from emotional reactions to provocative social situations and to less tolerance for, and inhibition 
of, frustration (Barkley, Edwards, Laneri, Fletcher, & Metevia, 2001b).  
Recent research shows that the problems with inhibition are first identified (at age 3-4 
years) in the hyperactive behavior of preschool children.  These symptoms are then compounded 
by an increase in those related to inattention over the next few years (by age 5-7 years).  The 
symptoms related to sluggish cognitive tempo that characterize the predominantly inattentive 
subtype arise even later (ages 8-10; Hart, Lahey, Loeber, Applegate, & Frick, 1995).  Whereas 
the symptoms of hyperactivity decline by adolescence, inhibitory problems remain as evidenced 
by difficulties with self-control, disregard for the consequences of one’s impulsive actions, and a 
diminished valuing of future goals over immediate gratification (Hart et al., 1995).   
It is important to note that it has not been consistently established that a diagnosis of 
ADHD predicts deficient inhibitory control after controlling for various demographic factors 
such as age and socioeconomic status.  Second, tests purportedly measuring impulsivity assess 
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additional cognitive factors, thereby precluding identification of the specific problematic 
psychological processes for children with ADHD.  Children with ADHD may perform worse on 
these tasks due to an aversion to long delays, motivational problems, or problems adjusting to 
different instructions rather than because of poor inhibitory control (Stevens, Quittner, 
Zuckerman, & Moore, 2002).  
ADHD and Executive Functioning 
The conceptualization of ADHD as deficits in executive functioning has primarily been 
supported by neurological and neuropsychological research.  For example, research comparing 
the neuroanatomy of children with and without ADHD show that children with the disorder have 
decreased blood flow to the frontal lobes (Grodzinsky & Diamond, 1992).  Magnetic resonance 
imaging (MRI) scans have revealed that non-ADHD children have slightly larger right frontal 
lobes than left; however, children with ADHD tend to lack this asymmetry, which may explain 
their deficits in sustained attention, a process associated with the right frontal lobe (Hynd, 
Semrud-Clikeman, Lorys, Novey, & Eliopulas, 1991).  Further evidence for executive 
functioning deficits in ADHD are illustrated by case studies of patients with frontal lesions.  
These patients often display the hallmark behavioral symptoms of ADHD such as hyperactivity, 
distractibility, and impulsivity.  Thus, several researchers have hypothesized that the behavioral 
symptoms of ADHD are linked to executive functioning deficits (Barkley, 1997b).   
One key aspect of executive functioning that is important in self-regulation is working 
memory (Chelonis et al., 2002).  Working memory is the capacity to hold information in the 
mind and use it to guide behavior, particularly across time and toward future goals.  According to 
Barkley (1997b), poor behavioral inhibition, as is seen in children with ADHD, should have 
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resultant deficits in working memory.  This hypothesis is in agreement with several proposed 
models of working memory that suggest attention to a stimulus that is to be remembered is the 
determinant of success on memory tasks.  Research has shown that children with ADHD perform 
poorly on tasks of working memory, including repetition of digits forwards and backwards, 
mental arithmetic, the Freedom of Distractibility Scale of the Wechsler Intelligence Scale for 
Children (WISC-III), and the Tower of Hanoi compared to non-ADHD control children (West, 
Houghton, Douglas, & Whiting, 2002).  
Executive functions are distinct from other mental functions such as sensation, 
perception, or memory.  There is, however, considerable overlap with domains such as attention, 
reasoning, and problem solving and with certain components of learning and memory 
(Biederman et al., 2004).  While some research does indicate that deficits in executive 
functioning are regularly found, after a review of the research literature, Halperin & Schulz 
(2006) found that, “at the group level executive functioning measures do not appear to have the 
sensitivity or specificity to adequately classify most individuals with ADHD relative to normal 
controls.” Halperin and Schulz (2006, p. 562) go on to say, the specificity of deficits to inhibitory 
control or executive functions is unlikely because children and adults with ADHD have 
repeatedly been found to differ from controls on a wide array of ‘non-executive’ cognitive 
functions such as motor coordination, perception, language, visuomotor integration, and learning 
and memory. (p. 563). 
Kempton et al. (1999) found that non-medicated ADHD children were impaired on tasks 
of executive functioning, including planning ability, movement time, attentional set shifting and 
spatial working memory.  These cognitive impairments however, did not occur in medicated 
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children with ADHD, possibly suggesting that stimulant medication normalizes executive 
functioning in ADHD.   
ADHD and Memory 
 Cognitive functions that are affected in ADHD also comprise memory processes (Krauel 
et al., 2007).  Recent imaging studies have revealed that ADHD patients show less activation in 
prefrontal areas during working memory tasks than healthy subjects (Schweitzer et al., 2000).  
Schon, Hasselmo, Lopresti, Tricarico, and Stern (2004) demonstrated that functional anatomic 
overlap occurs between active maintenance of object information in working memory and 
successful encoding into long-term memory in the prefrontal cortex and the limbic system.   
     Specific memory deficits associated with ADHD have become better understood in recent 
studies, which tend to show deficits only for tasks that depend on more complex, organizational 
components of memory (Kaplan, Dewey, Crawford, & Fisher, 1998).  Implicit and explicit 
memory are two forms of memory that have often been contrasted with one another in other 
clinical and developmental contexts, but implicit memory has not been well-studied in ADHD 
(Aloisi, McKone, & Heubeck, 2004).  Implicit memory refers to an influence or facilitation in 
performance based on some previous experience in the absence of conscious recollection, 
whereas explicit memory depends on conscious recollection (Burden & Mitchell, 2005).  
 Karatekin (2004) found that children with ADHD do not appear to have generalized 
impairments in working memory, but they may be more prone to specific impairments in 
working memory related to the ability to divide attention during tasks.  This finding supports 
suggestions that inconsistencies for finding memory differences in ADHD across the literature 
may stem from a lack of specificity when characterizing memory deficits (Kaplan et al., 1998).  
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Mealer, Morgan, and Luscomb (1996) found that children with ADHD had more memory 
difficulties than their peers without ADHD on general memory, but more particularly on visual 
memory and verbal learning, which are more dependent on active processing and storage of 
information during the test session.  By contrast, the ADHD group performed comparably to the 
non-ADHD group when stimuli were readily visible during testing (e.g., picture completion, 
picture arrangement.  
 In 2002, Stevens et al. found that children with ADHD performed poorer than children 
without the disorder on working memory task.  Children in the ADHD group were able to recall 
fewer digits than children in the control group when both processing and storing information 
were required.  This finding is consistent with previous research indicating that working memory 
is a major problem for these children (Mariani & Barkley, 1997).  These results carry additional 
significance because performance on the working memory task was not dependent on skills 
acquired in specific academic domains, such as reading.  Other researchers have also begun to 
disentangle impairments in working memory from difficulties with reading or mathematical 
operations (Mariani & Barkley, 1997).  
Memory storage and retrieval have been related to executive functioning and children 
with ADHD have been found to perform poorly on verbal fluency and pair associate tasks 
(Hoeppner et al., 1997).  Kaplan et al., (1998) found that when tested using the Wide Range 
Assessment of Memory and Learning (WRAML), a test of memory in both the verbal and non-
verbal domains, children with ADHD scored lower than age-matched controls on the General 
Memory Index, which taps both immediate and delayed recall.  Dewey et al. (2001) found that 
using the WRAML2 increased diagnostic acuity when used with other assessment measures.  
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Sergeant (2000) propose that memory is not an independent cognitive process.  Instead, memory 
function is highly related to allocation of attention and other executive functions related to 
utilization of efficient rehearsal strategies, as well as activation and motivation.  
 The WRAML subtests all require some type of “on the spot” learning and processing that 
would be more susceptible to disruption by attention problems than would be other types of 
cognitive activity (Mealer, Morgan, & Luscomb, 1996).  This 1996 study found that participants 
with ADHD scored significantly lower than the non-ADHD control group on the WRAML, 
including the General Memory Index, Visual Memory Index, and Learning Index, with the 
Learning Index displaying the greatest different between groups.  At the subtest level, the most 
noticeable differences took place on the Finger Windows and Verbal Learning; Visual Learning, 
and Sound Symbol were very close to reaching significance.    
Children with ADHD performed poorer on the WRAML, consistently reporting lower 
scores on subtests including Finger Windows, Verbal Learning, Sentence Memory, and Number 
Letter Memory (Kaplan et al., 1998).  All of these subtests require immediate processing and 
recall of novel material.  The fact that these subtests assess verbal and non-verbal working 
memory is of interest because other studies have shown that children with ADHD generally have 
less difficulty processing and retaining information in the non-verbal domain (Webster, Hall, 
Brown, & Bolen, 1996).  It is unclear if the performance of children with ADHD on these tasks 
is due to deficits in working memory or due to more global deficits.  The subtests that seem to 
cluster around attention and concentration are Number Letter Memory, Sentence Memory and 
Finger Windows, the same subtests are also associated with working memory (Kaplan et al., 
1998).  Attentional resources must be allocated to prolonging stimuli within working memory.  If 
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attention is drawn away from stimuli in working memory, the representation may decay before 
rehearsal strategies allow for a more lasting memory trace to be created.  Therefore, attentional 
processes are integral to working memory functioning.  
Memory tasks that are usually selected for psychopharmacological studies are tests such 
as Pair Associate Learning, Delayed Matching to Sample, or simple recognition tasks for words 
or figures (Frazier, Demaree, & Youngstrom, 2004).  These tests, however, do not permit a 
careful dissection of the memory process into its several components.  The demonstration of a 
positive stimulant effect on such tests can be interpreted simply in terms of an initial encoding 
process effect, and it is this component that would be predicted to improve if stimulant memory 
effects were mediated by simple attentional change or some other, indirect mechanism (Frazier et 
al., 2004).  Improvement in learning in the absence of change in immediate recall or span of 
apprehension would suggest a drug effect on the storage process and/or the efficiency with which 
information in retrieved (Evans, Gualtieri, & Amara, 1986).  The memory tests above do not 
discriminate these important factors; however, the WRAML2 incorporates this type of learning 
and memory.  
Other cognitive deficits would also give the appearance of reduced working memory 
capacity.  In particular, children with ADHD appear to have difficulty applying executive 
functions to manipulate information within the working memory buffer.  For example, children 
and adults with ADHD appear to have more difficulty with memory updating, which is 
selectively removing information from the working memory buffer to make room for new 
information (Roodenrys, Koloski, & Grainger, 2001).  This would, in effect, limit the working 
memory capacity by taking up space with information bits that are no longer relevant.  
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Experimental evidence suggests that the capacity of working memory in children with 
ADHD is intact and that deficits in working memory function are more related to deficits in the 
attentional/executive function components modulating the function of working memory 
(Deshazo, 2001).  This component of the memory system can accommodate approximately seven 
individual bits of information at a time.  Once a stimulus has entered the working memory store, 
it begins to decay after approximately 30 seconds unless its memory trace is prolonged by 
utilizing a mnemonic or rehearsal strategy (Roodenrys et al., 2001).  Barkley (1997b) has 
proposed that children with ADHD have difficulty with this prolongation process.  Mehta, 
Goodyer, and Sahakian (2004) found that methylphenidate improved performance on tasks of 
working memory, visual search, and attentional-set shifting.   
ADHD and Medication 
Stimulant medication, particularly methylphenidate (MPH), is the most common 
treatment for the management of ADHD.  Studies estimate that 2.8% of elementary school-aged 
children are taking medication for the management of ADHD with stimulants representing 99% 
of the medications prescribed (Goldman, Genel, Bezman, & Slanetz, 1998).  Several hundred 
control studies have been conducted on MPH and support its effectiveness in the management of 
major symptoms of ADHD (Barkley, DuPaul, & Conner, 1999).  Research has suggested that 
between 72% and 94% of children with ADHD respond positively to a single stimulant when 
multiple doses are tried (Barkley, Conner, & Kwasnik, 2000).  Nevertheless, there is substantial 
inter-individual variability in drug response.  Some children respond best at the lowest dose of 
(2.5 – 5 mg) and deteriorate in their behavior with increasing dosage, while others show a peak 
response at the highest dose (Rapport, DuPaul, Stoner, & Jones, 1986).  Still others seem to show 
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a curvilinear type of response with optimal responding occurring in the middle dose ranges 
(Barkley et al., 2000).  Moreover, 25% (or perhaps more depending on the study) of ADHD 
children placed on a single stimulant medication, such as MPH, may show no positive response 
at all, and 3-5% may have an adverse behavioral reaction (Rapport, Donney, DuPaul, & Gardner, 
1994).  Moreover, research on the use of psychostimulants in patients with ADHD without 
hyperactivity showed a high rate of non-responders and no evidence of long term effects on 
academic achievement and learning.  It is not clear whether these results apply to patients with 
predominately inattentive ADHD (McCormick, 2003).   
The positive effects of MPH on attention and social behavior have been demonstrated 
through teacher ratings, parent report, direct observation of classroom behavior, and clinic based 
test of attention and impulse control (DuPaul, Anastopoulos, Kwasnik, Barkley, & McMurray, 
1996).  Methylphenidate is a stimulant drug related to amphetamine that acts to increase the 
synaptic concentration of dopamine and noradrenaline (catecholamines) by blocking their 
reuptake (Seeman & Madras, 1998).  “Drug-related improvements also occur in other domains of 
behavior, including aggression, handwriting, academic productivity and accuracy, persistence of 
effort, working memory, peer relations, emotional control, and participation in sports” (Barkley, 
2004).   
Although neuropsychological studies of ADHD have consistently found impairments on 
tests of executive function, there is still debate about the precise nature of such impairments 
(Pennington & Ozonoa, 1996).  For example, some studies using the Wisconsin Card Sorting 
Test (WCST) have reported deficits in attentional set shifting in children with ADHD 
(Gorenstein, Mammato & Sandy, 1989) while others have found no such impairments 
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(Grodzinsky & Diamond, 1992).  In addition, while studies of ADHD report poor performance 
on measures of impulsivity or response inhibition on the Continuous Performance Test (CPT) 
(Corkum & Siegel, 1993), on the Go-No-Go test (Shue & Douglas, 1992) and on time slowness 
for Trails B (Shue & Douglas, 1992), others found no impairments on these tests (Grodzinsky & 
Diamond, 1992).  Furthermore, some researchers have reported impairments of visuospatial 
processing (Grodzinsky & Diamond, 1992) while others have found no impairments in these 
functions (Korkman & Pesonen, 1994).  Finally, two studies have found impairments in planning 
ability, measured with the Tower of Hanoi task and the Wisconsin Card Sorting Test (WCST) 
(Weyandt & Willis, 1994).  However, in ADHD, stimulant medication has been found to 
improve performance on tests of executive function, especially when they are highly structured 
measures of attention or vigilance such as reaction time or continuous performance tests (Mehta 
et al., 2000).  These paradoxical findings suggest that children with ADHD may require “over-
focusing and perseveration” to perform within normal limits on tests which require sustained and 
organized effort.   
Spencer et al. (1996) reported that randomized controlled short term (less than 12 weeks) 
trials reported improvement in about 65–75% ADHD patients on MPH versus 5–35% on 
placebo.  Historically, one of the main drawbacks of the immediate release forms of MPH was 
the abbreviated duration of action.  Due to its short term action, MPH had to be administered two 
to three times daily.  This constraint necessitated administering the medication during the school 
which potentially created problems with peers and may have increased medication non-
compliance (Deshazo, 2001).   
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Longer acting MPH has been designed to overcome the drawbacks of short acting MPH.  
The Ritalin-Slow Release (SR) represented an attempt for increasing MPH’s duration of action.  
However, Ritalin-SR may have been less efficacious in a number of ways (Novartis, 2006).  In 
one study the SR preparation was noted to have slower onset of therapeutic action than the 
immediate release form of MPH (Pelham, Sturges, & Hoza, 1987).  Swanson et al. (1999) noted 
a loss in its initial effectiveness during the afternoon rating periods.  Explanations underlying 
SR’s diminished effectiveness may be attributed to a number of pharmacokinetic factors which 
included the delayed release of MPH, the lack of a steep absorption-phase and a flattened plasma 
curve concentration after the establishment of peak concentrations (Birmaher, Greenhill, Cooper, 
Fried, & Maminski, 1989).  Northup, Gulley, Edwards, and Fountain (2001) found results 
indicating that there is not necessarily any particular dose-response relationship between 
disruptive behavior and academic performance at the individual level.  The optimal dose for 
behavior change may have minimal, or even a detrimental, influence on the child’s cognition or 
learning (Hoeppner et al., 1997), or may result in adverse side effects at higher doses, such as the 
“zombie effect,” characterized by affective blunting, dysphoria, and social withdrawal (Teeter & 
Semrud-Clikeman, 1995).  
Since ADHD medication is taken orally, absorption and distribution occur more slowly 
and the peak onset of drug action is usually around one hour (Julien, 2001).  Just as the rates of 
absorption and distribution of a drug impact the onset and peak of a drug’s behavioral effects, the 
half-life of a drug is also correlated with the duration of behavioral effects.  The drug’s half-life 
generally refers to the amount of time required to eliminate half of a drug from the body (Julien, 
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2001).  There is some variance with respect to the half-lives and subsequent durations of action 
of the drugs commonly used to treat ADHD.   
 Another question with respect to timing has to do with the frequency of changing 
conditions.  Most traditional clinical trials that have used rating scales as endpoints rely on no 
sooner than weekly phase changes without repeating conditions (Evans et al., 1986).  Other 
studies, however, have evaluated the effects of different doses of medication by changing doses 
on a daily basis and repeating conditions (Northup, Fusilier, Swanson, Roane, & Borrero, 1997).  
Unfortunately, the literature offers little guidance as to which of these approaches is more 
advantageous.  Given the pharmacokinetic profiles of the commonly used medications, there is 
no pharmacological reason why different doses or even drugs could not be evaluated in a fairly 
rapid fashion, perhaps even daily (Deshazo, 2001).  It is likely that the outcome measures 
selected will influence, to some degree, the rapidity with which dose changes can be evaluated.  
Standardized rating scales and general clinical impressions which are not necessarily anchored to 
quantifiable changes in behavior may require more time for the raters to integrate judgments 
across time, whereas direct observation may be assessed in a more rapid fashion (Kollins, 2004).  





Participants   
 The sample consisted of 35 children.  Participants satisfied a traditional DSM-IV 
diagnosis for ADHD and were taking prescribed medication for this condition (see DSM-IV 
criteria below).  Diagnoses were made by professionals including pediatricians, master’s level 
mental health therapists, and nurse practitioners.  Diagnoses were verified by the author using a 
symptom checklist based on DSM-IV criteria (see Appendix A).  Forty-one participants 
responded to the study; 6 were disqualified from the study because they were not taking 
prescribed medication for ADHD.     
DSM-IV Criteria for ADHD 
A. Either 1 or 2: 
1. Six or more of the following symptoms of inattention have persisted for at least six 
months to a degree that is maladaptive and inconsistent with developmental level: 
Inattention. 
a) Often fails to give close attention to details or makes careless mistakes in schoolwork, 
work, or other activities. 
b) Often has difficulty sustaining attention in tasks or play activities. 
c) Often does not seem to listen when spoken to directly. 
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d) Often does not follow through on instructions and fails to finish schoolwork, chores, 
or duties in the workplace (not due to oppositional behavior or failure to understand 
instructions). 
e) Often has difficulty organizing tasks and activities. 
f) Often avoids, dislikes, or reluctant to engage in tasks that require sustained mental 
effort (such as schoolwork or homework). 
g) Often loses things necessary for tasks and activities (e.g. toys, school assignments, 
pencils, books, or tools). 
h) Is often easily distracted by extraneous stimuli. 
i) Is often forgetful in daily activities. 
2. Six or more of the following symptoms of hyperactivity-impulsivity have persisted for 
at least six months to a degree that is maladaptive and inconsistent with developmental 
level: 
 Hyperactivity. 
a) Often fidgets with hands or feet or squirms in seat. 
b) Often leaves seat in classroom or in other situations in which remaining seated is 
expected. 
c) Often runs about or climbs excessively in situations in which it is inappropriate (in 
adolescents or adults, may be limited to subjective feelings of restlessness). 
d) Often has difficulty playing or engaging in leisure activities quietly. 
e) Is often "on the go" or often acts as if "driven by a motor". 
f) Often talks excessively. 




g) Often blurts out answers before questions have been completed. 
h) Often has trouble awaiting turn. 
i) Often interrupts or intrudes on others (e.g., butts into conversations or games). 
B. Some hyperactive-impulsive symptoms that cause impairment were present before age 7 
years. 
C. Some impairment from the symptoms is present in two or more settings (e.g. at 
school/work and at home). 
D. There must be clear evidence of significant impairment in social, school, or work 
functioning. 
E. The symptoms do not happen only during the course of a Pervasive Developmental 
Disorder, Schizophrenia, or other Psychotic Disorder.   The symptoms are not better accounted 
for by another mental disorder (e.g., Mood Disorder, Anxiety Disorder, Dissociative Disorder, or 
a Personality Disorder). 
Based on these criteria, three types of ADHD are identified: 
1. ADHD, Combined Type: if both criteria A1 and B1 are met for the past 6 months. 
2. ADHD, Predominantly Inattentive Type: if criterion A1 is met but criterion B1 is not met 
for the past six months.    
3. ADHD, Predominantly Hyperactive-Impulsive Type: if Criterion B1 is met but Criterion 
A1 is not met for the past six months. 
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American Psychiatric Association (DSM-IV-TR), 2000 
Participants were required to be between the ages of 9 and 12-years.  The age range was 
restricted to 9-12 due to the significant cognitive changes that occur between the ages of 5-8, and 
the significant biological changes that occurs after the age of 12 (primarily for males).  This 
design was utilized to limit the possible noise a broad age range may have added to the study.  
The children were recruited from Tigard, OR and surrounding communities through 
recommendations from pediatricians, nurse practioners and other mental health providers.  The 
providers presented the participants with a flyer from the author, which briefly explained the 
study and how to contact the author in order to participate (Appendix B).    
The inclusionary criteria for participants included: (a) English as a primary language; (b) 
meeting the diagnostic criteria for Attention Deficit Hyperactivity Disorder as defined by the 
DSM-IV (see criteria above).  The child may present with any subtype of ADHD including: 
hyperactivity/impulsivity, inattention, or combined type; (c) taking prescribed medication for 
ADHD symptoms for at least three months with minimal side effects as reported by parent and 
child; (d) confirmation from the parent that their child may discontinue the use of his/her 
stimulant medication for a period of at least 72 hours; (e) having not been diagnosed with a 
significant neurological disorder such as autism, epilepsy, cerebral palsy, or recent head injury 
with any loss of consciousness.    
Due to the limited ethnic diversity of Tigard and the surrounding area, the majority of the 
participants were Caucasian.  However, there is no reason to expect ethnicity to be a relevant 
variable in this study, as the primary measure has shown no significant differences between 
principal ethnic groups (Sheslow & Adams, 2003).  The demographic characteristics of age, 
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gender, and ethnicity of the children who participated are displayed in Table 1.  The average age 
of participants was 11.0 (SD = 1.00, Skewness = -.749, Kurtosis = -.406) with the youngest 
participant 9-years-old, and the oldest participant 12-years-old.    
 
Table 1 
Frequency Distributions of Demographic Variable (N = 35) 
Variable Frequency Percentage 
Gender 
     Male 
     Female 
Age 
     9  
     10 
     11 
     12 

















     Caucasian 







The ADHD diagnostic categories of the participants in the study are presented in Table 2.  
As can be noted, the smallest ADHD subgroup, the hyperactive subtype, comprised 11% of the 
35 participants, while approximately a quarter of the participants presented with a diagnosis of 
the inattentive subtype of ADHD (26%).  The majority of the sample was diagnosed with ADHD 
combined type (64%).  Only a fraction of participants presented with a co-morbid diagnosis 
(6%).  Of the two participants with co-morbid diagnoses, one was diagnosed with Depressive 
Disorder, NOS, while the other was diagnosed with Adjustment Disorder with Depressed mood. 




Frequency Distributions of ADHD Profiles 
Variable Frequency Percentage 
 
Diagnosis 
     ADHD Hyperactive 
     ADHD Inattentive 










     Present 








     MPH 
     Adderall 
     Concerta 












     5 mg 









Co-morbid diagnoses were obtained from the parents who were made aware of the additional 
diagnoses by their health care provider (the first was diagnosed by a pediatrician, the second by a 
master’s level mental health therapist).  Also in Table 2 is found the prescribed medications used 
by the participants.  The most common dosage of the participant’s medication was a 5 mg dosage 
(74%), while the additional participants were prescribed dosages at 10 mg (26%).  These figures 
represent the amount of medication taken per dose; they do not necessarily represent the total 
milligrams ingested per day.   
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Both male and female participants were accepted for participation, however research 
shows that the prevalence of ADHD is higher in males than in females (4:1 in community 
samples; 9:1 in clinical samples; Barkley, 1997b).  The proportion of males to females in the 
present study was approximately 3:1.    
Instruments 
 The Wide Range Assessment of Memory and Learning, 2nd Edition (WRAML2). All 
participants were administered the Wide Range Assessment of Memory and Learning Second 
Edition (Sheslow & Adams, 2003).The WRAML2 is an individually administered test battery 
designed to assess memory ability.  It was designed to be used for clinical assessments of 
memory, including evaluation of immediate and/or delay recall as well as differentiating between 
verbal, visual or more global memory deficits. (Sheslow & Adams, 2003).  The WRAML2 
consists of six core subtests, seven delayed memory tasks, two subtests designed to assess 
working memory, and four recognition memory subtests (see Figure 1).  The core subtests yield 
three indexes including verbal memory, visual memory, and attention/ concentration (each with a 
mean of 100 and a standard deviation of 15).  These three indexes combine to form the General 
Memory Index.    
The WRAML2 was standardized using a sample of 1,200 individuals ranging in age from 
5-90 (Sheslow & Adams, 2003).  The reliabilities of the three core indexes range from .85 to .93 
for children between the ages of 9 to 12 years.  The reliabilities of the six core subtests ranges 
from .78 to .95 for children between the ages of 9 to 12 years.  The reliabilities of the optional 
subtests range from .72 to .96 for children between the ages of 9 to 12 years.  The WRAML2  




Figure 1. The three core WRAML2 indexes and their contributing subtests. 
 
used Cronbach’s coefficient alpha to assess the internal consistency reliabilities for all of the 
subtests and indexes.  The median coefficient found across the norm sample ranged from .86 to 
.93, with a median of .93 for the General Memory Index.  Table 3 provides the person and item 
separation reliabilities for the WRAML2. 
The Verbal Memory Index subtests include Story Memory and Verbal Learning.  The 
Story Memory subtest requires the examinee to listen to, and then recall as many parts of two 
stories as can be remembered.  The Verbal Learning subtest is a list-learning task.  The examinee 
is read a list of 16 words which is followed by an immediate free-recall trial.  Three additional 
list presentation/recall trials follow (Sheslow & Adams, 2003).    
 The Visual Memory subtests include Design Memory and Picture Memory.  Design 
Memory consists of five different cards with geometric designs.  Each card is presented for a 
five-second exposure, followed by a 10-second delay.  The examinee is then asked to draw what 
he/she remembers.  For the Picture Memory subtest, the examinee is shown four common but  
GENERAL MEMORY 
 INDEX 
Verbal Memory  
Index 
 
























Person and Item Separation Reliabilities for WRAML2 Subtests 







Story Memory .94 .99 
Design Memory  .92 1.00 
Verbal Learning  .88 .99 
Picture Memory  .85 1.00 
Finger Windows  .91 1.00 




Verbal Working Memory .85 .99 
Symbolic Working Memory  .87 1.00 
Sentence Memory  .92 1.00 
 
Delay Recall Subtests 
  
Story Memory Delay Recall  .93 .99 




Story Memory Recognition  .78 .99 
Design Memory Recognition  .56 .99 
Picture Memory Recognition  .60 .99 
Verbal Learning Recognition  .58 .98 
 
 
visually complex scenes (e.g., a classroom) for 10 seconds.  Following each scene, a similar but 
alternate scene is presented and the examinee is asked to identify elements that have “been 
moved, changed or added” (Sheslow & Adams, 2003).    
 The Attention/Concentration subtests include Finger Windows and Number-Letter.  The 
Finger Windows subtest requires the examinee to duplicate a demonstrated sequence of visual 
locations on an 8x10 plastic card.  The Number-Letter subtest requires the examinee to repeat a 
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sequence of single digits and letters that are verbally presented.  For both the Finger Windows 
and Number-Letter subtests, the sequence to be replicated by the participant gradually becomes 
longer and more challenging.    
 There are three optional subtests for the WRAML2.  Requiring less rote memory than the 
Number-Letter subtest, the Sentence Memory requires the examinee to repeat a series of longer 
and longer sentences read by the examiner.  On the Verbal Working Memory subtest, 
participants 9-12 years of age listen to a list of words, some of which are animals and some of 
which are not.  Initially, participants are asked to repeat all of the words, recalling the animal 
words first followed by the non-animal words in any order.  The examinee is then asked to 
complete a more difficult task that requires him/her to recall the animals in order of their typical 
size (smallest to largest), followed by all the non-animal words in any order.  Symbolic Working 
Memory requires the examinee to actively manipulate information presented prior to recall, over 
two levels of difficulty.  For the first level, the examiner randomly dictates a series of numbers 
and asks the examinee to point to the numbers dictated in correct numerical order on a stimulus 
card.  For the second task, a random number and letter series is dictated and the examinee is 
asked to point to the dictated numbers followed by the dictated letters, each in correct order on 
number and alphabet cards.     
The WRAML2 also includes delayed recall and recognition subtests.  Story Memory 
Delay Recall requires the examinee to again recall details of the two short stories read about 15 
minutes earlier in the session.  The Story Memory Recognition subtest allows the examinee to 
provide details of the stories using a 3-item, multiple choice format.  The Verbal Learning Delay 
Recall subtest requires the examinee to recall the list of words the examiner read over the four 
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trials the last one of which occurred about 15 minutes earlier in the session.  Thereafter, the 
Verbal Learning Recognition subtest requires the examinee to respond with a “yes” or “no” to 
indicate if a word read by the examiner was recognized from the original list.  Design Memory 
Recognition requires the examinee to respond with a “yes” or “no” when presented with 
previously seen geometric shapes from the Design Memory subtest.  Picture Memory 
Recognition requires the examinee to respond to “yes” or “no” options on the Picture Memory 
Recognition Form based on whether the examinee believes the pictured element was previously 
seen on one of the four original or alternate picture stimuli used on the core Picture Memory 
subtest (Sheslow & Adams, 2003).  Table 4 categorizes the core, optional, delay recall, and 
recognition subtests. 
 
Table 4  
WRAML2 Optional, Delay Recall, and Recognition Subtests 
Core Subtests Delayed Recall Subtests Recognition Subtests Optional Subtests 
Story Memory Story Memory Delay Recall Story Memory Recognition  
Verbal Learning Verbal Learning Delay Recall Verbal Learning Recognition  
Design Memory  Design Memory Recognition  
Picture Memory  Picture Memory Recognition  
Finger Windows    
Number-Letter    
   Sentence Memory 
   Verbal Working 
Memory 
 
   Symbolic 
Working Memory 
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Wechsler Abbreviated Scale of Intelligence (WASI). The Wechsler Abbreviated Scale 
of Intelligence (WASI; Zhu, 1999) is an abbreviated IQ measure that is composed of four 
subtests and can be administered to participants ages 6-89.  The subtests of the WASI include: 
Vocabulary, Similarities, Block Design, and Matrix Reasoning.  Scores earned on the 
Vocabulary and Similarities subtests can be combined to yield a Verbal IQ; scores on the Block 
Design and Matrix Reasoning subtests can be combined to yield a Non-Verbal IQ; all four 
subtests combine to yield a Full Scale IQ.  “The subtests were chosen for their strong association 
with general cognitive abilities and for their relationship to constructs of intelligence, such as the 
verbal and performance and crystallized and fluid dichotomies” (Zhu, 1999).  Figure 2 shows the 
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The Vocabulary subtest consists of items that are similar to the Vocabulary subtests of 
the WISC-IV and the WAIS-III.  For each, the examiner asked the examinee to define a word.  
The Block Design subtest consist of thirteen modeled or printed patterns that the examinee must 
replicate using two-colored cubes.  The Similarities subtest requires the examinee to explain the 
similarity between two common objects or concepts.  Matrix Reasoning, involves a series of 
patterns that the examinee must determine the relationship being depicted, and then choose of the 
five options provided finishes the analogy (Zhu, 1999).  Each of the WASI’s subtests presents 
items in increasing order of difficulty and the subtest is discontinued when a ceiling rule is met.     
The four subtests Cronbach’s coefficient alpha reliabilities reported on a child’s sample, 
range from .86 to .93 for Vocabulary, from .81 to .91 for Similarities, from .84 to .93 for Block 
Design, and from .86 to .96 for Matrix Reasoning (Ryan & Brown, 2005). 
Across the 11 age groups of the children’s sample, the Cronbach’s coefficient alpha reliabilities 
for the IQ scales range from .92 to .95 for both the Verbal Intelligence Quotient (VIQ) and 
Performance Intelligence Quotient (PIQ), and from .95 to .97 for the FSIQ. (Zhu, 1999). 
On average, the FSIQ of the WISC-III and the WASI differ by less than one point (Zhu, 1999). 
Continuous Performance Test (CPT-II). The Continuous Performance Test (CPT-II; 
Conners, 2000) is a vigilance task that requires the participant to remain attentive to changing 
stimuli presented on a computer screen and to respond by pressing a key when specific stimuli 
appear.  The CPT-II is designed to be cognitively demanding and sensitive to the detection of 
inattentive and impulsive symptoms of ADHD (Edwards et al., 2007).  In 2003, Epstein et al. 
found the CPT-II measures predicted the presence of most all of the ADHD symptoms listed by 
the DSM-IV.  As such, these T-scores provide an index of how deviant an individual’s score 
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pattern is from a nonclinical sample, and whether the obtained results match a clinical or 
nonclinical sample.  
The participant’s performance is converted into a T-score.  The T-score is then scored 
against the CPT-II interpretation guidelines, which can be found in Table 5.  The overall index 
score uses discriminate functions to assess the likelihood that an examinee’s responses fit those 
given by individuals with ADHD (Weis & Totten, 2004).  The split-half reliability correlations 




Guidelines for Interpreting CPT-II T Scores and Percentiles 
 
T Score  Percentile   Guideline 
 
65+        90+        Markedly atypical  
60-64      85-89       Moderately atypical  
55-59      70-84       Mildly atypical 
45-54      31-69       Within the average range 
40-44      15-30       Good performance 
Under 40   Under 15       Very good performance 
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The standard protocol of the CPT-II test uses a short training exercise prior to the 
administration of the full test to ensure that the respondent fully understands the task.  After the 
training exercise, the test administration is begun; it is a requirement of the standardized 
procedure that an examiner remains present (Conners & MHS Staff, 2000).  CPT-II respondents 
are required to press a computer space bar or click a mouse whenever any letter except the letter 
‘X’ appears anywhere on the computer screen.  The inter-stimulus intervals (ISIs) are 1-, 2-, and 
4-seconds with a display time of 250 milliseconds.  The CPT paradigm is a test structure 
consisting of blocks, each containing 20 trials (letter presentations).  The presentation order of 
the different ISIs varies between blocks (Conners & MHS Staff, 2000).  The administration time 
of the CPT-II is approximately 14 minutes.    
Procedure 
This study followed the ethical guidelines of the American Psychological Association 
and approval was obtained from the Internal Review Boards (IRB) of George Fox University 
before the study commenced.  Thereafter, the author provided local pediatric health care 
providers with flyers (Appendix B) which outlined the study and provided contact information 
for the author. Parents of potential participants contacted the author by phone prior to the study 
and oral consent and the initial appointment time for testing was obtained.  The author then 
assessed the participants’ eligibility for the study by asking each parent about their child’s 
diagnoses, their prescribed medication, and reviewed the exclusionary criteria.  The parent was 
asked to both bring the child’s medication to the first session and have the child discontinue 
his/her use of psychostimulant medication for a period of 72-hours.  Parents and participants 
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were informed that participation was voluntary and withdrawal may occur at any time.  An 
appointment time was made for the initial session of testing.   
Half of the participants were randomly placed in the medication – placebo sequence and 
half in the placebo – medication sequence.  Consequently, there were two evaluation sessions 
(i.e., Session 1 and Session 2) and the context of each can be found in Table 6.  Session 2 was 
scheduled for 72 hours after Session 1 to attempt to control the amount of time the medication 
had been out of the participant’s system.  Random sequencing was done with the assistance of an 
Excel random number generator.  The random number generator used the total number of 
participants and randomly split them into two groups with participants in the first group being 
placed in the medication-placebo sequence and the participants in the second group placed in the 
placebo-medication sequence.    
 
Table 6 
Activities Associated with Each Testing Session 
  Session 1 Session 2 
Signed consent form (parent); Collected 
medication. Participant ingests medication. 
 
Parent and participant completed the ADHD 
checklist. 
Participant ingested placebo capsule in 
envelope. 
 
Parent and participant provided additional 
background information. 
 
The participant completed the CPT-II. 
 
The participant completed the CPT-II. 
The participant completed half of the WASI. The participant completed other half of the 
WASI. 
The participant completed half of the 
WRAML2. 
The participant completed other half of the 
WRAML2. 
Made an appointment for session two. Child received participation prize. 
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When the parent and participant arrived for Session 1, the parent provided the examiner 
with a pill of the participant’s psychostimulant medication.  The medication and placebo were 
placed into identical opaque capsules.  The placebo capsules contained gelatin.  A master’s level 
therapist, a separate individual from the examiner and the author, placed the medication in the 
capsules and gave the child the capsule that corresponded to the treatment condition they had 
randomly assigned to.  The additional capsule was placed into an envelope for Session 2.  This 
preserved the double blind study, which requires that neither the examiner nor the participant 
were aware of the medication sequence.  During this time the parents were asked to read and sign 
the consent form (see Appendix C).  Parents and participants were informed that the participants 
are joining in a study that gives the researcher information about the child’s memory.  After the 
parent had signed the consent form, he/she and his/her child were escorted by an examiner to a 
testing room.  The examiner, with the assistance of the parent, then used the ADHD symptom 
checklist that is comprised of DSM-IV diagnostic criteria to confirm the child’s ADHD 
diagnosis (see Appendix A).  No participants were disqualified at this time as they all met the 
DSM-IV diagnostic criteria, however six were disqualified during the initial phone screening 
process.   
After completion of the ADHD checklist, the parent was asked to sit in a waiting area 
while the participant completed the assessments.  The participant first completed the CPT-II.  








Content of Each WASI Subtest Groupings that was Administered on Medication and Placebo. 
Test Session 1 Test Session 2 
Vocabulary Similarities 
Matrix Reasoning Block Design 
 
 
The participant then completed half of the WRAML2 (see Table 8).  The time from 
ingestion of the medication or placebo to the completion of half of the WASI in Session 1 was 
approximately 45 minutes.  This gave enough time for the medication to take affect before 
beginning the WRAML2.    
 
Table 8   
 
Content of Each of WRAML2 Subtest Groupings that was Administered on Medication Placebo.  
Test Session 1 Test Session 2 
Story Memory Verbal Learning 
Story Memory Recall Verbal Learning Recall 
Story Memory Recognition Verbal Learning Recognition 
Design Memory Picture Memory 
Design Memory Recognition Picture Memory Recognition 
Finger Windows Number-Letter 
Symbolic Working Memory Working Memory 
Sentences  
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Upon arriving for Session 2, the participant took the remaining capsule from the 
individual envelope designated from Session 1, which contained either the medication or placebo 
depending on the treatment group to which the participant was assigned.  After ingestion of the 
capsule, the parent and participant were escorted to a testing room where the examiner collected 
additional background information (e.g., age, sex, diagnostic subtype, educational level, and 
dosage of medication) that was not obtained during the initial phone interview (see Appendix D).  
The examiner also collected additional data concerning the participants ADHD symptomology 
from both the parent and participant (see Appendix E).    
The participant then completed the CPT-II for a second time.  After completion of the 
CPT-II, the participant completed the additional half of the WASI and the additional half of the 
WRAML2.  The time from ingestion of the second capsule, to completion of the WASI in 
Session 2 was approximately 45 minutes.  Again, this allowed time for the medication to become 
active.  Information on the typical ADHD medication can be found in Table 9.   After the 
completion of the WRAML2 in Session 2, the participant completed their participation in the 
study.  The participant was then given their token for participation.  Tokens included two $10 
gift certificates to Blockbuster, one for each session.  The parents also received a $10 gas gift 
card.    
One doctoral student from George Fox University assisted the author in data collection.  
The author and examiner administered the WRAML2 and WASI, while the author alone 
administered the CPT-II to the participants on dates arranged by the author.  The author and 
examiner had successfully completed a course in cognitive assessment in which they received 
formal training and demonstrated proficiency with the administration of the WRAML2.  The  




ADHD Medications, Half-lives, Peak Action, and Duration of Action. 
Medication Half-Life Peak Action Duration of Action 
Adderall  1-3 hrs 1-2 hrs 4-10 hrs 
Adderall XR 7-9 hrs 1-4 hrs 9 hrs 
Concerta 1-3 hrs 1-3 hrs 4-8 hrs 
Ritalin 1-3 hrs 1-3hrs 4-6 hrs 
Ritalin SR 1.5-5 hrs 1-4 hrs 5 hrs 
Strattera 5 hrs 1-2 hrs 12-24 hrs 
 
Note: The information obtained for Table 9 was adapted from Witcher et al. (2003); Kollins 
(2004); Deglin & Vallerand (2005).  Adderall XR stands for extended release; Ritalin SR stands 
for slow release.    
 
author also held a review session with the assisting examiner to ensure knowledge of the 
WRAML2, WASI, and the CPT-II.  Both the author and the examiner scored the protocols they 
administered.  The scored protocols were then reviewed by the other to assess for any scoring or 
tabulation errors.    
Shafritz, Marchione, Gore, Shaywitz, and Shaywitz (2004) used a 72-hour period of time 
during which the participant could not be on their medication before participating in their study.  
They reported that, “we attempted to control for medication history by ensuring that participants 
were medication-free for at least 72 hours before testing; this does not eliminate possible long-
term modulation of neural functioning stemming from methylphenidate use.”  Therefore, both 
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sessions were scheduled after the participant had not ingested his/her medication for at least 72 
hours. At the beginning of both sessions, the author asked the parent if it has been at least 72 
hours since their child last ingested their psychostimulant medication. 






To test Hypotheses 1 through 15, a multivariate repeated measures analysis of variance 
(MANOVA) was used for the 15 subtests of the WRAML2, which served as dependent 
variables; session (on medication; on placebo) served as the between groups independent 
variables.  To test hypotheses 16-19, a separate repeated measures MANOVA was conducted 
including standard scores from the four subtests of the WASI as dependent variables, and session 
(on medication; on placebo) as the between group independent variables.  WRAML2 subtest 
performance was represented by scaled scores, with the standardization sample mean of 10 and a 
standard deviation of 3.  For the WASI, the subtest means are represented as T scores, with a 
standardization mean of 50 and standard deviation of 10.  Subtests in a domain were 
counterbalanced with treatment condition, such that some participants completed specific 
subtests while in the medication condition and others completed specific subtests while in 
placebo condition.  Please refer to the methods section for details on counterbalancing of the 
conditions.    
Contrary to the research hypotheses, there was no overall performance difference 
between participants on medication and those on placebo for subtests of the WRAML2 (Wilks λ 
= .66, F(15, 19) = .65, p > .05).  Nor were there an overall difference between participants on 
medication and those on placebo for the subtests of the WASI (Wilks λ = .81, F(4, 30) = 1.71, p 
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> .05).  The analyses from the MANOVA are reported below as they relate to each of the 
hypotheses.  Table 10 shows the performance across both conditions for all participants.. 
 
Table 10 
Performance in Medication and Placebo Conditions 
Order    Mean  Std. Deviation         Effect Size  N 
WRAML2 Subtests 
Story Memory  
 Medication  9.00                   1.372                                     18 
 Placebo  9.06                   1.819                                     17 
 Total   9.03                   1.581              -.040               35 
 
Story Recall 
 Medication  8.83                   1.543                                     18 
 Placebo  9.24                   1.715                                     17 
 Total   9.03                   1.618              -.250               35 
 
Story Recognition  
 Medication                9.06                   1.474                                     18 
 Placebo             9.47                   1.807                                     17 
 Total                         9.26                   1.633              -.249               35  
 
Design Memory  
 Medication             8.44                    1.381                                      18 
 Placebo             8.76                    1.888                                      17 
 Total                         8.60                    1.631              -.194               35 
 
Design Memory Recognition 
 Medication             8.61                    1.577                                            18 
 Placebo             8.82                    1.629                                    17 
 Total                         8.71                    1.582               -.131              35 
 
Finger Windows  
 Medication           7.56                    1.580                                     18 
 Placebo             8.35                    1.935                                     17 
 Total                         7.94                    1.781               -.447              35 
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Table 10. Performance in Medication and Placebo Conditions. (Continued) 
 
Order    Mean  Std. Deviation         Effect Size  N 
Symbolic Working Memory  
 Medication             8.33                    1.455                                     18 
 Placebo             8.59                    1.938                                     17 
 Total                         8.46                    1.686               -.151              35 
 
Sentence Memory  
            Medication             11.17                    1.948                                     18 
 Placebo             10.88                    1.728                                     17 
 Total                         11.03                    1.823                .157              35 
 
Verbal Learning  
 Medication             8.78                    1.665                                     18 
 Placebo             9.18                    1.944                                     17 
 Total                         8.97                    1.790               -.220              35 
 
Verbal Learning Recall  
 Medication             8.72                    1.565                                     18 
 Placebo             8.76                    1.300                                     17 
 Total                         8.74                    1.421               -.020              35 
 
Verbal Learning Recognition  
 Medication             9.11                     1.568                                    18 
 Placebo             8.82                     1.510                                    17 
 Total                         8.97                     1.524                   .189          35 
 
Picture Memory  
 Medication             9.06                     1.955                                    18 
 Placebo             9.18                     2.007                                    17 
 Total                         9.11                     1.952                  -.061          35 
 
Picture Memory Recognition  
 Medication             8.89                     1.367                                    18 
 Placebo             9.12                     1.409                                    17 
 Total                         9.00                     1.372                  -.166          35 
 
Number Letter  
            Medication             9.22                     1.801                                    18 
 Placebo             8.94                     1.345                                    17 
 Total                         9.09                     1.579                   .176          35 
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Table 10. Performance in Medication and Placebo Conditions. (Continued) 
 
Order    Mean  Std. Deviation         Effect Size  N 
Verbal Working Memory  
 Medication             8.22                     1.437                                    18 
 Placebo             8.29                     1.160                                    17 




 Medication            52.61                     4.629                         18 
 Placebo            52.88                     3.638                         17 
 Total             52.74                     4.118       -.064          35 
 
Matrix Reasoning  
 Medication            52.06                     5.116                         18 
 Placebo            54.35                     3.952                         17 
 Total             53.17                     4.668       -.501          35 
 
Similarities  
 Medication                52.17                     4.926                         18 
 Placebo           51.94                     4.100                         17 
 Total            52.06                     4.478        .051          35 
 
Block Design  
 Medication           52.39                     4.002                         18 
 Placebo           53.53                     4.460                         17 
 Total            52.94                     4.207       -.269          35 
 
Note: WRAML2 = Wide Range Assessment of Memory and Learning, 2nd Edition. WASI =    
Wechsler Abbreviated Intelligence Scale.  
 
Hypotheses 
 Hypothesis 1. Participants diagnosed with ADHD will score higher on the Story Memory 
subtest of the WRAML2 in the psychostimulant medication condition than when they are in the 
placebo condition.  
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There were no significant differences evidenced across treatment conditions for Story 
Memory, (F(1, 33) = .01, p > .05).  Contrary to the hypothesis, Story Memory performance was 
non-significant for psychostimulant medication and placebo conditions. 
Hypothesis 2. Participants diagnosed with ADHD will score higher on the Story Memory 
Recall subtest of the WRAML2 in the psychostimulant medication condition than when they are 
in the placebo condition.  
There were no significant differences evidenced across treatment conditions for the Story 
Memory Recall subtest, (F(1, 33) = .53, p >.05).  Contrary to the hypothesis, Story Memory 
Recall performance was non-significant for psychostimulant medication and placebo conditions. 
 Hypothesis 3. Participants diagnosed with ADHD will score higher on the Story Memory 
Recognition subtest of the WRAML2 in the psychostimulant medication condition than when 
they are in the placebo condition.  
There were no significant differences evidenced across treatment conditions for the Story 
Memory Recognition subtest, (F(1, 33) = .56, p >.05).  Contrary to the hypothesis, Story 
Memory Recognition performance was non-significant for psychostimulant medication and 
placebo conditions. 
 Hypothesis 4. Participants diagnosed with ADHD will score higher on the Design 
Memory subtest of the WRAML2 in the psychostimulant medication condition than when they 
are in the placebo condition.  
There were no significant differences evidenced across treatment conditions for the 
Design Memory subtest, (F(1, 33) = .33, p >.05).  Contrary to the hypothesis, Design Memory 
performance was non-significant for psychostimulant medication and placebo conditions. 
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 Hypothesis 5. Participants diagnosed with ADHD will score higher on the Design 
Memory Recognition subtest of the WRAML2 in the psychostimulant medication condition than 
when they are in the placebo condition.  
There were no significant differences evidenced across treatment conditions for Design 
Memory Recognition subtest, (F(1, 33) = .15, p >.05).  Contrary to the hypothesis, Design 
Memory Recognition performance was non-significant for psychostimulant medication and 
placebo conditions. 
 Hypothesis 6. Participants diagnosed with ADHD will score higher on the Verbal 
Learning subtest of the WRAML2 in the psychostimulant medication condition than when they 
are in the placebo condition.  
There were no significant differences evidenced across treatment conditions for Verbal 
Learning subtest, (F(1, 33) = .43, p >.05).  Contrary to the hypothesis, Verbal Learning 
performance was non-significant for psychostimulant medication and placebo conditions. 
 Hypothesis 7. Participants diagnosed with ADHD will score higher on the Verbal 
Learning Recall subtest of the WRAML2 in the psychostimulant medication condition than when 
they are in the placebo condition.  
There were no significant differences evidenced across treatment conditions for Verbal 
Learning Recall subtest, (F(1, 33) = .01, p >.05).  Contrary to the hypothesis, Verbal Learning 
Recall performance was non-significant for psychostimulant medication and placebo conditions. 
 Hypothesis 8. Participants diagnosed with ADHD will score higher on the Verbal 
Learning Recognition subtest of the WRAML2 in the psychostimulant medication condition than 
when they are in the placebo condition.  
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There were no significant differences evidenced across treatment conditions for Verbal 
Learning Recognition subtest, (F(1, 33) = .31, p >.05).  Contrary to the hypothesis, Verbal 
Learning Recognition performance was non-significant for psychostimulant medication and 
placebo conditions. 
 Hypothesis 9. Participants diagnosed with ADHD will score higher on the Picture 
Memory subtest of the WRAML2 in the psychostimulant medication condition than when they 
are in the placebo condition.  
There were no significant differences evidenced across treatment conditions for the 
Picture Memory subtest, (F(1, 33) = .03, p >.05).  Contrary to the hypothesis, Picture Memory 
performance was non-significant for psychostimulant medication and placebo conditions. 
 Hypothesis 10. Participants diagnosed with ADHD will score higher on the Picture 
Memory Recognition subtest of the WRAML2 in the psychostimulant medication condition than 
when they are in the placebo condition.  
There were no significant differences evidenced across treatment conditions for the 
Picture Memory Recognition subtest, (F(1, 33) = .24, p >.05).  Contrary to the hypothesis, 
Picture Memory Recognition performance was non-significant for psychostimulant medication 
and placebo conditions. 
 Hypothesis 11. Participants diagnosed with ADHD will score higher on the Finger 
Windows subtest of the WRAML2 in the psychostimulant medication condition than when they 
are in the placebo condition.  
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There were no significant differences evidenced across treatment conditions for the 
Finger Windows subtest, (F(1, 33) = 1.79, p >.05).  Contrary to the hypothesis, Finger Windows 
performance was non-significant for psychostimulant medication and placebo conditions. 
 Hypothesis 12. Participants diagnosed with ADHD will score higher on the Number 
Letter subtest of the WRAML2 in the psychostimulant medication condition than when they are 
in the placebo condition.  
There were no significant differences evidenced across treatment conditions for the 
Number Letter subtest, (F(1, 33) = .27, p >.05).  Contrary to the hypothesis, Number Letter 
performance was non-significant for psychostimulant medication and placebo conditions. 
 Hypothesis 13. Participants diagnosed with ADHD will score higher on the Symbolic 
Working Memory subtest of the WRAML2 in the psychostimulant medication condition than 
when they are in the placebo condition.  
There were no significant differences evidenced across treatment conditions for the 
Symbolic Working Memory subtest, (F(1, 33) = .20, p >.05).  Contrary to the hypothesis, 
Symbolic Working Memory performance was non-significant for psychostimulant medication 
and placebo conditions. 
 Hypothesis 14. Participants diagnosed with ADHD will score higher on the Verbal 
Working Memory subtest of the WRAML2 in the psychostimulant medication condition than 
when they are in the placebo condition.  
There were no significant differences evidenced across treatment conditions for the 
Verbal Working Memory subtest, (F(1, 33) = .03, p >.05).  Contrary to the hypothesis, Verbal 
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Working Memory performance was non-significant for psychostimulant medication and placebo 
conditions. 
 Hypothesis 15. Participants diagnosed with ADHD will score higher on the Sentence 
Memory subtest of the WRAML2 in the psychostimulant medication condition than when they 
are in the placebo condition.  
There were no significant differences evidenced across treatment conditions for the 
Sentence Memory subtest, (F(1, 33) = .21, p >.05).  Contrary to the hypothesis, Sentence 
Memory performance was non-significant for psychostimulant medication and placebo 
conditions. 
 Hypothesis 16. Participants diagnosed with ADHD will score higher on the Vocabulary 
subtest of the WASI in the psychostimulant medication condition than when they are in the 
placebo condition.  
There were no significant differences evidenced across treatment conditions for the 
Vocabulary subtest, (F(1, 33) = .037, p >.05).  Contrary to the hypothesis, Vocabulary 
performance was non-significant for psychostimulant medication and placebo conditions. 
 Hypothesis 17. Participants diagnosed with ADHD will score higher on the Matrix 
Reasoning subtest of the WASI in the psychostimulant medication condition than when they are 
in the placebo condition.  
There were no significant differences evidenced across treatment conditions for the 
Matrix Reasoning subtest, (F(1, 33) = 2.2, p >.05).  Contrary to the hypothesis, Matrix 
Reasoning performance was non-significant for psychostimulant medication and placebo 
conditions. 
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 Hypothesis 18. Participants diagnosed with ADHD will score higher on the Similarities 
subtest of the WASI in the psychostimulant medication condition than when they are in the 
placebo condition.  
There were no significant differences evidenced across treatment conditions for the 
Similarities subtest, (F(1, 33) = .02, p >.05).  Contrary to the hypothesis, Similarities 
performance was non-significant for psychostimulant medication and placebo conditions. 
 Hypothesis 19. Participants diagnosed with ADHD will score higher on the Block 
Design subtest of the WASI in the psychostimulant medication condition than when they are in 
the placebo condition.  
There were no significant differences evidenced across treatment conditions for the Block 
Design subtest, (F(1, 33) = .64, p >.05).  Contrary to the hypothesis, Block Design performance 
was non-significant for psychostimulant medication and placebo conditions. 
 






 The present study was an investigation to assess if the use of psychostimulant medication 
would result in higher scores on measures of memory and intelligence among participants with 
ADHD.  The results of the analyses showed that psychostimulant medication did not 
significantly alter performance on measures of verbal or visual memory, nor on verbal or visual 
measures of intelligence compared to placebo conditions.   
In the current study, the medicated ADHD children were receiving an individually 
prescribed dose of stimulant medication.  Previous research has found that improvements in 
cognitive functioning are seen in a dose-dependent linear curve (i.e., low doses effect cognitive 
aspects more significantly than higher doses (2.5-5; Hoeppner et al., 1997).  It could be argued 
that medication dose influenced performance in this study (i.e., if the dosages were too high to 
effect cognitive processes and solely treated behavior symptoms; Kempton, 1999).  The present 
study utilized varied dosages (both 5 and 10 mg) along with various types of prescribed 
medications.  It is possible that by not examining one specific type and/or dosage of 
psychostimulant medication the study was impacted in unknown ways.   
A subjective scale was provided for parents (see Appendix D) to rate their children on 
different areas including: the child’s overall behavior (1 = very poor to 10 = very good), the 
child’s level of distractibility (1 = not distractible to 10 = very distractible), the child’s activity 
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level (1 = not active to 10 = very active), and the parent’s perception on the effects of their 
child’s medication (1 = not effective to 10 = very effective).  Means for the parent ratings were as 
followed: Behavior (mean: 6.5; sd = 1.42); Distractibility (mean: 7.8; sd = 1.65); Activity level 
(mean: 7.2; sd = 1.57); Effect of medication (mean: 7.0; sd = 1.53).  Per the parent’s report, it 
appears that the psychostimulant medication has been moderately effective in treating their 
children’s symptoms of distractibility and hyperactivity.  While the medication seems to be 
addressing the behavioral concerns of the children’s ADHD symptoms, it seems to be doing little 
to help memory or IQ processes as research indicates that cognitive processes are often found 
helpful at low doses (2.5 - 5 mg; Pliszka et al., 2006).  
The current study found that results of 12 of the 14 subtests of the WRAML2 and 3 of the 
4 subtests of the WASI were higher in the placebo condition.  Of the 19 subtest procedures 
utilized, 15 (78.95%) had lower levels of performance associated with the medication condition.  
While some of the 15 subtests differences were small, and none statistically significant, 
nonetheless, when subhected to a chi-square analysis, the number of subtests with lower 
medication performance across the 19 subtests was found to be greater than would be expected 
by chance (χ2(1) = 8.78, p < .01).  Therefore, there is a trend suggested that medication is not 
helpful, and might, in fact, even be subtly antagonistic to recall. 
While most of the CPT-II data were lost, data pertaining to Table 5 were salvageable.  
This data suggest that, according to the CPT-II ADHD symptom severity scores, the participants 
in the study fell within the average range of ADHD symptom severity.  The participants in the 
medication condition for Session 1 yielded a mean CPT-II symptom severity score of 51.31 (sd = 
8.04); while the placebo condition for Session 1 yielded a mean of 51.94 (sd = 8.11).  Likewise 
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the results of medication condition for Session 2 yielded a mean CPT-II symptom severity score 
of 50.42 (sd = 8.17); while the placebo condition for Session 2 yielded a mean of 54.99 (sd = 
6.79).  It could be argued that while the participants met clinical criteria for ADHD their level of 
symptom severity was minimal and therefore the results were muted due to the lack of severe 
clinical symptomology within the participant pool.  It may also be argued that the participants, 
according to the CPT-II, did not meet DSM-IV diagnostic criteria for ADHD.    
Swanson (1993) conducted a comprehensive examination of 341 reviews of the effects of 
stimulant medication on children with ADHD. His review found that psychostimulant 
medication was ineffective for 25 to 40 percent of children with ADHD in terms of behavioral 
improvements.  Additionally, there was no evidence of significant improvement in reading, 
athletic or game skills, proactive social skills, learning and achievement other than improved 
attending.  If the reviewed research indicated no changes in behavioral symptoms for up to 40% 
of participants, then it is likely that a much higher percentage of participants experienced no 
effects, or even negative effects, on cognitive components.  “Inconsistent MPH-achievement 
findings may be in part due to differences in cognitive and behavioral dose-response 
relationships. When differential MPH dose-response relationships have been reported, lower 
doses typically improve academic behavior, with little or no additional benefit found for higher 
doses” (Hale et al., 2011). 
Barkley et al., (2000) stated that it is extremely difficult to evaluate drug response in an 
outpatient setting.  “[An outpatient setting] will compromise the clinician’s abilities to 
systematically evaluate actual drug responding, thereby undermining clinical judgments of drug 
and dose effectiveness.”  Similar to the results described above, at the group level Barkley et al., 
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(2000) found no response to medication per attention and inhibition in varied dosages in an 
outpatient research setting.  
 Stimulants have been the mainstay of psychopharmacologic treatment of ADHD for over 
fifty years.  Methylphenidate is the most frequently prescribed stimulant (Goldman et al., 1998).  
While research continues to support the notion that psychostimulant medication improves 
behavioral characteristics (Barkley, 2004), the research is still unclear how effective 
psychostimulant medication is for aspects of memory such as sustained attention, encoding, 
retention, or recognition.  The present study would suggest that psychostimulant medication has 
no demonstrable effects on children’s performance on short term and delayed memory tasks.   
Limitations 
 The CPT-II was used as an additional diagnostic measure to Appendixes A & E.  
However, it should be noted that the computer on which the CPT-II data was stored, crashed 
rendering the data inaccessible. This limited the amount of data that could be utilized from the 
CPT-II.  
 The data that were retrieved from the CPT-II suggested that the severity of the 
symptomology of the participants was within the average range.  This appeared to limit the 
results as it is probable that participants with more severe clinical presentation may have gained 
more cognitive benefit from psychostimulant medication than participants with severity of 
symptoms in the average range.   
 The study also included all three diagnostic subtypes of ADHD, as well as several 
different medications and two different doses. Perhaps examining one specific diagnostic 
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subtype, one specific type of medication, or one specific dose of medication may have yielded 
different results. 
Future Direction 
 It will be important for future research in this area to focus on each specific subtype of 
ADHD, to determine which, if any, may be more sensitive medication effects.  The present study 
had a limited number of ADHD inattentive and hyperactive subtypes.  Future studies examining 
medication effects on each of the three subtypes would be beneficial.  
 Research utilizing specific dosing standards, as well as specific medication types, would 
allow for medication effects on intellectual and memory processes to be examined more closely 
as there is ongoing debate in the research about which dosage of which medication yields more 
reliable results for both behavior and cognition (Hoeppner et al., 1997).  Studies which 
investigate medication doses below recommended, at recommended, and higher than 
recommended doses for the three or four most commonly used medications would be greatly 
beneficial. 
 Memory retrieval and executive functioning are closely related.  Future research 
integrating memory and executive functioning measures may created a more well rounded 
picture of medication effects on memory functioning and related executive functioning skills 
such as working memory, recall, and inhibition.  
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Inattention: Six (or more) of the following symptoms must have persisted for at least 6 months to 
a degree that is maladaptive and inconsistent with developmental level: 
 
_____ Fails to give attention to details or makes careless mistakes in schoolwork, chores or 
other activities 
 
_____ Has difficulties sustaining attention in tasks or play activities 
 
_____ Does not seem to listen when spoken to directly 
 
_____ Does not follow through on instructions and fails to finish schoolwork, chores, or duties 
in the home (not due to oppositional behavior or failure to understand directions) 
 
_____ Has difficulty organizing tasks and activities 
 
_____ Avoids or strongly dislikes tasks that require sustained mental effort (such as schoolwork 
or homework) 
 
_____ Loses things necessary for tasks or activities (such as school assignments, pencils, books, 
or toys) 
 
_____ Easily distracted by extraneous stimuli 
 
_____ Forgetful in daily activities 
 
Hyperactivity-Impulsivity: Six (or more) of the following symptoms must have persisted for at 
least six months to a degree that is maladaptive and inconsistent with developmental level: 
 
_____ Fidgets with hands or feet or squirms in seat 
 
_____ Leaves seat in classroom or in other situations in which remaining in seat is expected 
(such as the dinner table) 
 
_____ Runs about or climbs excessively in situations where it is inappropriate (in adolescents 
this may be limited to a subjective feeling of restlessness) 
 
_____ Has difficulty playing or engaging in leisure or play activities quietly  
 
_____ Is “on the go” or acts as if “driven by a motor” 
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_____ Talks excessively  
 
_____ Blurts out answers to questions before the questions have been completed 
 
_____ Has difficulty waiting in lines or awaiting turn in games or group situations 
 
_____ Interrupts or intrudes on others (such as butting into conversations or other activities) 
 
Additional Diagnostic Criteria 
 
_____ Some hyperactive-impulsive or inattentive symptoms that caused impairment were 
present before age 7. 
 
_____ Some impairment from the symptoms is present in two or more settings. 
 
_____ There must be clear evidence of clinically significant impairment in social, academic, or 
occupations functioning. 
 
_____ The symptoms do not occur exclusively during the course of a Pervasive Developmental 
Disorder, Schizophrenia, or other Psychotic Disorder and are not better accounted for by another 
mental disorder.  
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$20 GIFT CARD OPPORTUNITY!! 
 
What:  A study on memory and the effects that psychostimulant    medication has on the 
memory of children with Attention Deficit/Hyperactivity Disorder (ADHD). As a 
token “Thank you”, each child will receive a $20 gift certificate to Blockbuster 
Video for his/her participation. The parent will also receive a $10 gas card for 
their time and effort transporting their children. 
  
Who:  Participants will be children between the ages of 9-12 who have been diagnosed 
with ADHD and are taking medication to control these symptoms. Children will 
be asked to complete a brief IQ assessment and a memory assessment, both of 
which will be divided between the 2 sessions. They will also do a computerized 
assessment that is much like a computer game. Session 1 will be approximately an 
hour, and session 2 will only take about 40 minutes. Participation is completely 
voluntary and may stop at any time 
 
Where:  All tasks will be administered by a trained doctoral psychology student at the 
Tigard High School Health Center. 
 
Why:  The results may help children with this condition, and their families, to be better 
informed about the effects stimulant medication has on memory in children with 
ADHD. 
 




I hope that you and your child will be able to help with this project. To schedule your 
sessions, please contact Ben Dunagan at (503)333-7072 or email at 
bdunagan05@georgefox.edu by May 15th.  I look forward to working with you and your 
child. 




















I understand that my child is a willing participants in this doctoral research investigating 
the effects of psychostimulant medication on the memory of children with ADHD. As a 
part of this study, my child will be asked to complete a cognitive assessment and a 
memory assessment, supply information about my child’s ADHD symptoms and 
diagnosis, and be willing to have my child assessed both on and off of his/her prescribed 
medication. These assessments will be completed over two sessions.  
 
I understand that myself, and my child will have the opportunity to take part in a 
discussion with the person administering the assessments regarding the procedures 
involved. I understand that myself and my child will be able to receive a summary of the 
study’s results.  
 
I understand that my child may stop his/her involvement at any point, with no 
explanation necessary. 
 
If I have any questions that the person administering these tests cannot answer or 
concerns about the testing process, I can contact Ben Dunagan, MA. Mr. Dunagan is 
being supervised by Dr. Wayne Adams of George Fox University. Mr. Dunagan is 
available at 503-333-7072 or by email at: bdunagan05@georgefox.edu. 
 
 
_____________________________  ______________________________ 
Printed Participant’s Name   Participant’s Signature 
 
 
_____________________________  ______________________________ 








Date:_____/_____/_______   ___________________________ 
      Test Examiner’s Signature 
 
 
























Child’s Name: ___________________________________________________________ 
   First   Middle   Last 
 
Date of Birth: ______/______/_______  Age: ___________ 
 
Sex (circle one please):   Male  Female 
 
Ethnicity (circle one please): Caucasian African American Asian    Hispanic  
    Other: ______________________ 
 
Grade (last grade passed): ___________________ 
 
Parents’ Names: __________________________________________________________ 
 
Contact Information 
 What is the best way to contact you? (circle one please):  Phone  Email 
 
Phone Number: ___________________  Email: ________________________ 
 
Home Address: ___________________________________________________________ 
*Note: Contact information is used ONLY for scheduling appointments and will NOT be 
used in the research. 
 
Child’s Diagnosis: ________________________________________________________ 
 






Side Effect(s): ___________________________________________________________ 
 
Allergic to milk?      Yes  No 
 
Does your child have vision or hearing difficulties?  Yes  No 
 
If yes, explain: ___________________________________________________________ 




1st Appointment: _________________________________________________ 
2nd Appointment: _________________________________________________ 
 
Has it been 72 hours since your child ingested his/her psychostimulant medication? 
 
   Yes   No 
Parent Ratings 
How is your child’s behavior overall? 
1 2 3 4 5 6 7 8 9 10 
How is your child’s distractibility? 
1 2 3 4 5 6 7 8 9 10  
How is your child’s activity level? 
1 2 3 4 5 6 7 8 9 10 
How has the medication affected your child’s behavior? 
1 2 3 4 5 6 7 8 9 10 
 
 













ADHD Symptom History 
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Has your child ever been diagnosed with an emotional or behavioral problem other than 
ADHD?  Yes  No 
      




At what age was he/she diagnosed? ___________________________________________ 
 




























Benjamin Dunagan, PsyD. 







May 2011  Doctorate (PsyD.) 
George Fox University  
Graduate Department of Clinical Psychology 
Newberg, OR, APA Accredited 
 
May 2007 Master of Arts: Clinical Psychology 
George Fox University  
Graduate Department of Clinical Psychology  
Newberg, OR, APA Accredited 
   
Dec. 2004 Master of Science: Community Counseling 
   University of Nebraska at Kearney  
Kearney, NE, CACREP Accredited 
 
May 2002   Bachelor of Science: Psychology; Minor in Sociology 





Oct. 2010 – Aug. 2011 Licensed Professional Counselor – State of Colorado 




Jan. 2011 – Current Kaiser Permanente 
    Denver, CO 
    Emphasis: Health Psychology 
Responsibilities: 
 Provide personality and diagnostic psychological 
assessments.   
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 Provide in-takes and individual psychotherapy with 
heavy caseload. 
 Interdisciplinary work environment.  
 
    
July 2009 – June 2010 Internship (APA Accredited) 
  Jersey Shore University Medical Center 
  Neptune, NJ 
Emphasis: Primary Care Psychology, Behavioral Pain 
Management, & Medical Issues    
Rotations: 
  Consultation and Liaison 
 Consultation and evaluations with a variety of medical 
and psychological diagnoses including substance abuse. 
 Comprehensive psychological assessments on inpatient 
psychiatric unit with co-morbid medical issues.  
Behavioral Medicine 
 Primary care psychology including post partum 
depression evaluations. 
 Provided pain management interventions in conjunction 
with physicians at musculoskeletal clinic. Discussed 
rationale for pain medication treatment and 
prescriptions.  
 Interventions included progressive muscle relaxation, 
diaphragmatic breathing, sleep management, cue-
controlled relaxation, stress management, & CBT for 
pain management.  
Inpatient Treatment 
 Provided group and individual therapy for patients with 
SMPI, eating disorders, and other chronic conditions. 
 Provided outpatient referrals and recommendations. 
Neuropsychological Assessment 
 Neuropsychological assessment with acute medical 
patients on rehabilitation unit. 
 Patient presentations included stroke, toxic/metabolic or 
anoxic encephalopathy, neurosurgical interventions for 
malignant neuroplastic disease or hydrocephalus shunt 
placement, traumatic brain injury, cardiac crisis, multiple 
sclerosis, dementia, spinal cord surgery and general 
debility due to multiple & coexisting medical conditions. 
Outpatient Clinic 
 Outpatient psychotherapy with adults and adolescents.  
 Co-facilitated group: Coping with Chronic Medical 
Conditions.  
Aug. 2008 – June 2009 Pre-Internship 
Kaiser Permanente 
  Portland, OR 
  Population: Adult, Adolescent, & Children Outpatient 
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Emphasis: Neuropsychological Assessment & Primary Care 
Psychology 
Responsibilities: 
 Provided weekly outpatient neuropsychological 
assessments for patients with both chronic and acute 
medical issues.  
 Provided personality and diagnostic psychological 
assessments.   
 Provided in-takes and individual psychotherapy with 
heavy caseload. 
 Interdisciplinary work environment.  
Supervisor: Ron Sandoval, PhD. 
 
Aug. 2007 – June 2008 Practicum II 
Oregon State Hospital 
  Salem, OR 
  Population: Adult Inpatient 
Emphasis: Neuropsychological & Cognitive Assessment with 
SPMI 
   Responsibilities:  
 Provided weekly cognitive assessments. 
 Provided bi-weekly neuropsychological assessments for 
patients dealing with chronic medical problems. 
 Presented at the Neuropsychological Grand Rounds: 
“Neuropsychological Functioning of Patient with 
Multiple Myeloma and Renal Failure” 
 Interdisciplinary work environment.  
Supervisor: James Clay, PsyD.  
 
Aug. 2006 – Aug. 2007   Practicum I 
Lifeworks Northwest: Cedar Mill & Tigard sites 
  Portland & Tigard, OR 
  Population: Adult Outpatient 
    Emphasis: Individual Psychotherapy 
    Responsibilities: 
 Provided individual psychotherapy to patients presenting 
with a variety of diagnoses. Heavy case load. 
 Conducted in-take interviews, provided diagnosis, and 
treatment planning. 
 Treated diverse clientele and diagnostic issues. 
 Offered a paid position at the end of the practicum. 
Supervisor: Ken Ihli, PhD.  
 
Jan. 2006 – April 2006 Pre-Practicum training: GFU Counseling Center 
  George Fox University, Newberg, OR 
  Population: Adult Outpatient   
    Emphasis: Individual Psychotherapy 
    Responsibilities: 
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 Provided individual psychotherapy with university 
students. 
 Conducted in-take interviews, treatment planning, 
mental status, and goal setting. 
 Completed case presentations to supervision group. 
Supervisor: Sally Hopkins, PsyD. 
 
July 2004 – Dec. 2004 Masters Level Internship: Richard Young Hospital 
  Kearney, NE  
  Population: Inpatient adolescents 
    Emphasis: Individual, Group, & Family Psychotherapy 
    Responsibilities:  
 Provided individual, group, and family psychotherapy. 
 Responsible for treatment planning and case notes. 
 Work closely with the child psychiatrist. 
 Interdisciplinary work environment. 
Supervisor: Kathleen Shundoff, PhD.  
 
Jan. 2004 – May 2004 Masters Practicum: University of Nebraska at Kearney 
Counseling Center 
  Kearney, NE   
    Population: Adults, Adolescents, and Children 
    Emphasis: Individual Psychotherapy 
Responsibilities:  
 Provided individual psychotherapy. 
 Responsible for treatment planning and case notes. 
 Regular case presentations to supervision group. 
Supervisor: David Hof, PhD. Ed. 
 
May 2002 – Oct. 2003 St. Francis Hospital Alcohol and Drug Treatment Center 
  Grand Island, NE 
  Population: Adults and Adolescents 
    Emphasis: Substance Abuse 
    Responsibilities:  
 Worked with clients with substance abuse issues. 
 Supervised client’s daily activities. 
 Co-facilitated group therapy. 
 
Jan. 2001 – May 2002 Undergraduate Practicum: Center Point Treatment Center 
    Lincoln, NE  
    Population: Adolescents 
    Emphasis: Substance Abuse 
    Responsibilities:  
 Worked with adolescents who were inpatient substance 
abuse treatment center. 
 Co-facilitated substance abuse and eating disorders 
group therapy. 
 Observed individual and group therapy. 
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Supervisor: Bill McNeil, PhD. 
 
Jan. 2000 – May 2001 Undergraduate Practicum: Northwest Family Center 
    Lincoln, NE  
    Population: Adolescents 
    Emphasis: Adolescent Social Skills 
    Responsibilities:  
 Worked with adolescents who had sexual abuse history. 
 Facilitated involvement in social activities. 
 Monitored progress concerning school work. 




2010   New Jersey Psychological Association Foundation  
 Research into Causes and/or Treatment of Social Problems 
Award: The Effects of Medication on Memory for Children 
Diagnosed with ADHD. 
 
2008   Richter Grant for Travel 
 Awarded $1200.00 Richter Grant to fund travel to APA 
convention to present research on autism. 
 
2007   Richter Grant for Research 
 Awarded $750.00 Richter Grant for research concerning 
autism.  
 
2007   Richter Grant for Research 
 Awarded $4865.00 Richter Grant to fund dissertation 
concerning ADHD. 
 
2007-2011  Doctoral Dissertation:  
 Title: “The Effects of Medication on Memory in Children 
Diagnosed with ADHD”. 
 Investigates the impact of psycho-stimulant medication on 
memory.  
 Dissertation Chair: Wayne Adams, PhD., ABPP 
 
 2007  Research Assistant: George Fox University 
 Title: “Assessment of Long-term Memory” 
 Paid position collecting data for dissertation measuring long 
term memory.  
 
2006   Research Assistant: George Fox University 
 Title: “Shame Recognition in Grade School Students” 
 Responsible for data collection. 
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2006   Research Assistant: George Fox University 
 Title: “Everyday Memory Scale”.  
 Paid position collecting norms for memory assessment. 
 
 2005                         Research Vertical Team Member 
 Meet twice a month to discuss, evaluate process, 
methodology, and design of group and individual research 
projects.   
                                       Supervisor: Wayne Adams, PhD., ABPP 
 
2002     Senior Research Project: Nebraska Wesleyan University  
Title: “Assessing Personality Differences and Classroom 
Approval Ratings” 




2011  Presentation: 2011 APA Conference: Washington, DC. Poster 
presentation. “The Effects of Medication on Memory in Children 
Diagnosed with ADHD”. 
  
2009 Lennen, D.T., Dunagan, B.J., Lamb, G.D., & Hall, T.A. (2010). Verbal 
prowess equals higher IQ: Implications for evaluating autism. Research 
in Autism Spectrum Disorders. 
 
2008  Presentation: 2008 APA Conference: Boston, MA. Oral presentation.  
“Verbal prowess equals higher IQ: Implications for evaluating autism”. 
 
2008 Presentation: OSH Neuropsychological Grand Rounds Case 
Presentation: “Neuropsychological Functioning of Patient with Multiple 




2007 – 08 Graduate Assistant: Neuropsychological Assessment: George Fox 
University Responsibilities: Teach usage of various neuropsychological 
assessment instruments and assess competence of students on said 
instruments. Paid position.  
 
2008 Research and Design: George Fox University – Associate Professor 
Master’s program. 
Responsibilities: Class lecture, grading, and supervision of research 
projects. 
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2008 Research and Statistics: George Fox University – Associate Professor 
Master’s program. 
Responsibilities: Class lecture, grading, and supervision of research 
projects.  
 
2008  Lifespan and Development: George Fox University – Guest Lecturer 




2008 – Present  National Academy of Neuropsychology 
 
2005 – Present  American Psychological Association 
 
2005 – Present   American Psychological Association of Graduate Students 
 
2002 – 2006  Nebraska Counseling Association 
    
 
 
